Thrombosis pathways and therapeutic strategies
Moataz Dowaidar
Abstract
Thrombosis is the world's leading cause of death, accounting for one of everyfour deaths. Atrial fibrillation is responsible for around a tenth of all ischaemicstrokes (AF) Antiplatelet drugs are the cornerstone of AT treatment andprevention. Long-term use of aspirin and clopidogrel has little advantage overeither agent alone in terms of stroke prevention. It does, however, significantlyraise the risk of bleeding complications. Direct oral anticoagulants are at least aseffective as warfarin in reducing stroke. Return to the tab on which you arrived.Bleeding is the most common side effect of all commercially approvedantiplatelet drugs. Thrombin, thrombine, and thromboembolism are also bloodclotting proteins that are deficient in certain patients to differing degrees.Thrombin is a platelet activator that plays a role in platelet-coagulation pathwaycrosstalk. All coagulated factors, with the exception of FXII, are required forhaemostasis. Extrinsic and typical pathway components are required byhaemostases. The key protease in the coagulation cascade is thrombin. Since thehaemostatic plugs have sealed the wound, the fibrinolytic system separates themfrom the vasculature. Nanomedicine has elegantly attempted to cure differentgene polymorphisms and mutations in complex disorders using gene therapyapproaches.